Moderna (NASDAQ:MRNA) Sets New 1-Year High - Here's What Happened

Key Points

• Moderna shares reached a new 52-week high, trading as high as $243 and gaining 6.6%, as investors positioned ahead of Phase 3 melanoma data and upcoming oncology presentations.
• Analyst sentiment has improved, including Oddo BHF’s price-target increase to $251, though the broader analyst consensus remains “Hold” with a $101.45 target price.
• Optimism is offset by risks including skepticism about the cancer-vaccine opportunity, continued insider selling under pre-arranged trading plans, and Moderna’s ongoing losses and negative profit margins.

Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) hit a new 52-week high on Tuesday. The company traded as high as $243.00 and last traded at $237.8580, with a volume of 11,413,108 shares changing hands. The stock had previously closed at $226.89.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Investors are positioning ahead of detailed Phase 3 melanoma results for Moderna’s personalized cancer therapy, expected to be presented Saturday. Positive data could strengthen the company’s oncology pipeline and support a broader re-rating. What's Going On With Moderna Stock Monday?
• Positive Sentiment: Oddo BHF raised its Moderna price target to $251 from $170, adding to bullish analyst sentiment and implying continued upside based on expectations for the company’s pipeline. Oddo BHF Adjusts Moderna Price Target
• Positive Sentiment: Moderna and Merck are expected to headline ESMO 2026 with cancer-related data, keeping the company’s personalized oncology program in focus. The event may provide additional evidence on the commercial potential of the partnership. Merck/Moderna to Headline ESMO 2026
• Neutral Sentiment: Moderna is being highlighted among biotech and AI-enabled healthcare investment ideas, reflecting interest in data-driven drug development and personalized medicine rather than a specific new financial announcement. AI Healthcare Stocks Article
• Neutral Sentiment: An article reviewing institutional views on MRNA may influence investor positioning, but the available headline does not identify a material change in consensus expectations. Investment Firms and Moderna
• Negative Sentiment: A critical analysis argues that the market may be overpricing Moderna’s cancer-vaccine opportunity, highlighting execution, clinical, and commercialization risks. This skepticism could increase volatility if upcoming data disappoint. Moderna: Sell the Cancer Vaccine Hype
• Negative Sentiment: Moderna President Stephen Hoge reported selling millions of dollars of company stock under a trading plan. The transactions may weigh on sentiment, although planned sales do not necessarily indicate a change in the company’s outlook. Stephen Hoge Sells Moderna Shares

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Piper Sandler upped their target price on Moderna from $77.00 to $167.00 and gave the stock an "overweight" rating in a research report on Thursday, August 20th. JPMorgan Chase & Co. lifted their price target on shares of Moderna from $40.00 to $77.00 and gave the company an "underweight" rating in a research report on Friday, August 21st. Singular Research raised shares of Moderna to a "hold" rating in a research report on Wednesday, September 23rd. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Moderna in a research note on Friday, August 28th. They issued a "hold" rating and a $125.00 price objective for the company. Finally, Wolfe Research raised shares of Moderna from an "underperform" rating to a "peer perform" rating in a report on Tuesday, August 25th. Seven analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $101.45.

Moderna Trading Up 6.6%

The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The company's 50 day moving average is $160.00 and its 200 day moving average is $92.42. The stock has a market capitalization of $96.60 billion, a price-to-earnings ratio of -30.26 and a beta of 1.09.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. During the same period last year, the business posted ($2.13) EPS. The business's quarterly revenue was up 2.1% on a year-over-year basis. On average, research analysts forecast that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

Insider Activity at Moderna

In related news, CFO Jamey Mock sold 34,836 shares of Moderna stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the sale, the chief financial officer directly owned 59,375 shares of the company's stock, valued at $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider directly owned 74,129 shares in the company, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 197,251 shares of company stock worth $33,875,904. Company insiders own 10.80% of the company's stock.

Institutional Trading of Moderna

A number of hedge funds have recently modified their holdings of MRNA. Western Pacific Wealth Management LP acquired a new position in shares of Moderna in the third quarter valued at $29,000. Fortitude Family Office LLC boosted its stake in Moderna by 53.1% during the third quarter. Fortitude Family Office LLC now owns 222 shares of the company's stock worth $43,000 after buying an additional 77 shares in the last quarter. Allied Private Wealth LLC bought a new stake in Moderna in the 2nd quarter valued at $30,000. Archer Investment Corp bought a new stake in Moderna in the 2nd quarter valued at $36,000. Finally, Canton Hathaway LLC bought a new stake in Moderna in the 1st quarter valued at $31,000. Institutional investors own 75.33% of the company's stock.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company's research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.